DrugPatentWatch Database Preview
Paratek Pharms Inc Company Profile
What is the competitive landscape for PARATEK PHARMS INC, and when can generic versions of PARATEK PHARMS INC drugs launch?
PARATEK PHARMS INC has two approved drugs.
There are nine US patents protecting PARATEK PHARMS INC drugs.
There are one hundred and seventy-three patent family members on PARATEK PHARMS INC drugs in thirty-nine countries.
Summary for Paratek Pharms Inc
| International Patents: | 173 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Paratek Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | 10,111,890 | Start Trial | Start Trial | ||||
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | POWDER;INTRAVENOUS | 209817-001 | Oct 2, 2018 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Paratek Pharms Inc | NUZYRA | omadacycline tosylate | TABLET;ORAL | 209816-001 | Oct 2, 2018 | RX | Yes | Yes | 9,724,358 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Paratek Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2987354 | Start Trial |
| Eurasian Patent Organization | 009175 | Start Trial |
| Slovenia | 2296464 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
